MediClin Forecast, price target & analysts
MediClin Target price 2026 - Analyst rating & recommendation
MediClin Classifications & Recommendation
MediClin Price Target
| Target Price | €6.63 |
| Price | €5.35 |
| Potential |
23.93%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target MediClin 2027 .
The average MediClin target price is €6.63.
This is
23.93%
register free of charge
€7.67
43.27%
register free of charge
€5.76
7.61%
register free of charge
|
|
| A rating was issued by 6 analysts: 5 Analysts recommend MediClin to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the MediClin stock has an average upside potential 2027 of
23.93%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million € | 804.32 | 813.65 |
| 5.13% | 1.16% | |
| EBITDA Margin | 15.13% | 14.25% |
| 4.87% | 5.81% | |
| Net Margin | 3.17% | 4.60% |
| 2.39% | 45.15% |
3 Analysts have issued a sales forecast MediClin 2026 . The average MediClin sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an MediClin EBITDA forecast 2026. The average MediClin EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 MediClin Analysts have issued a net profit forecast 2026. The average MediClin net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | 0.54 | 0.79 |
| 3.85% | 46.30% | |
| P/E | 6.79 | |
| EV/Sales | 0.60 |
3 Analysts have issued a MediClin forecast for earnings per share. The average MediClin EPS is
This results in the following potential growth metrics and future valuations:
Current MediClin Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| SOLVENTIS RESEARCH |
Locked
➜
Locked
|
Locked | May 07 2026 |
| SOLVENTIS RESEARCH |
Locked
➜
Locked
|
Locked | Feb 17 2026 |
| SOLVENTIS RESEARCH |
Locked
➜
Locked
|
Locked | Dec 04 2025 |
| SOLVENTIS RESEARCH |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| SOLVENTIS RESEARCH |
Locked
➜
Locked
|
Locked | May 08 2025 |
| SOLVENTIS RESEARCH |
Locked
➜
Locked
|
Locked | May 07 2025 |
| DZ BANK |
Locked
➜
Locked
|
Locked | Apr 22 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
SOLVENTIS RESEARCH:
Locked
➜
Locked
|
May 07 2026 |
|
Locked
SOLVENTIS RESEARCH:
Locked
➜
Locked
|
Feb 17 2026 |
|
Locked
SOLVENTIS RESEARCH:
Locked
➜
Locked
|
Dec 04 2025 |
|
Locked
SOLVENTIS RESEARCH:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
SOLVENTIS RESEARCH:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
SOLVENTIS RESEARCH:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
DZ BANK:
Locked
➜
Locked
|
Apr 22 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
